Search Results

By The ASCO Post Staff  / Tuesday, April 8, 2014 12:18 PM

Study Identifies Potential Predictor of Clinical Outcome in Patients With Lung Cancer Treated With MK-3475

Among patients with non–small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes, according to results of a phase I clinical trial presented at the American...